Effect of PPARγ ligands on IL-6 secretion by freshly isolated human primary BMSCs stimulated by KAS6/1 cells or TNFα
| Cells . | IL-6 production, ng/mL . | ||
|---|---|---|---|
| Control . | 15-d-PGJ2 . | Troglitazone . | |
| BMSCs | 38.10 ± 3.88 | 24.16 ± 4.50 | 22.73 ± 6.72 |
| BMSCs + KAS6/1 | 93.77 ± 5.70 | 33.71 ± 0.45* | 20.01 ± 2.30* |
| BMSCs + TNFα | 73.54 ± 4.47 | 24.29 ± 2.48* | 38.64 ± 2.71* |
| Cells . | IL-6 production, ng/mL . | ||
|---|---|---|---|
| Control . | 15-d-PGJ2 . | Troglitazone . | |
| BMSCs | 38.10 ± 3.88 | 24.16 ± 4.50 | 22.73 ± 6.72 |
| BMSCs + KAS6/1 | 93.77 ± 5.70 | 33.71 ± 0.45* | 20.01 ± 2.30* |
| BMSCs + TNFα | 73.54 ± 4.47 | 24.29 ± 2.48* | 38.64 ± 2.71* |
Human primary BMSCs were cocultured with KAS6/1 cells or stimulated with TNFα (5 ng/mL) and treated with 1 μM 15-d-PGJ2 or 10 μM troglitazone for 48 hours. IL-6 concentration was determined in supernatants. Values represent the mean plus or minus SE from 3 independent experiments (*P < .05, compared with control group). IL-6 concentration was not detectable in KAS6/1 cells.